GB2540638B - Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases - Google Patents

Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases

Info

Publication number
GB2540638B
GB2540638B GB1520656.8A GB201520656A GB2540638B GB 2540638 B GB2540638 B GB 2540638B GB 201520656 A GB201520656 A GB 201520656A GB 2540638 B GB2540638 B GB 2540638B
Authority
GB
United Kingdom
Prior art keywords
formulations
compound
ocular diseases
treating ocular
activates tie
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1520656.8A
Other languages
English (en)
Other versions
GB2540638A8 (en
GB201520656D0 (en
GB2540638A (en
Inventor
G Peters Kevin
Shalwitz Robert
Michael Janusz John
Duncan Smith Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aerpio Therapeutics LLC
Original Assignee
Aerpio Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics LLC filed Critical Aerpio Therapeutics LLC
Priority to GB1709419.4A priority Critical patent/GB2549865B/en
Publication of GB201520656D0 publication Critical patent/GB201520656D0/en
Publication of GB2540638A publication Critical patent/GB2540638A/en
Publication of GB2540638A8 publication Critical patent/GB2540638A8/en
Application granted granted Critical
Publication of GB2540638B publication Critical patent/GB2540638B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GB1520656.8A 2013-03-15 2014-03-14 Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases Active GB2540638B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1709419.4A GB2549865B (en) 2013-03-15 2014-03-14 Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361792868P 2013-03-15 2013-03-15
US201361792679P 2013-03-15 2013-03-15
US201361882048P 2013-09-25 2013-09-25
US201361882056P 2013-09-25 2013-09-25
US201461934570P 2014-01-31 2014-01-31
GB1411935.8A GB2516561B (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Publications (4)

Publication Number Publication Date
GB201520656D0 GB201520656D0 (en) 2016-01-06
GB2540638A GB2540638A (en) 2017-01-25
GB2540638A8 GB2540638A8 (en) 2017-03-15
GB2540638B true GB2540638B (en) 2018-01-17

Family

ID=51529957

Family Applications (3)

Application Number Title Priority Date Filing Date
GB1520656.8A Active GB2540638B (en) 2013-03-15 2014-03-14 Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
GB1709419.4A Active GB2549865B (en) 2013-03-15 2014-03-14 Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
GB1411935.8A Active GB2516561B (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
GB1709419.4A Active GB2549865B (en) 2013-03-15 2014-03-14 Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
GB1411935.8A Active GB2516561B (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Country Status (17)

Country Link
US (10) US9440963B2 (cg-RX-API-DMAC7.html)
EP (3) EP3607821B1 (cg-RX-API-DMAC7.html)
JP (3) JP6572201B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150129019A (cg-RX-API-DMAC7.html)
CN (2) CN109925312A (cg-RX-API-DMAC7.html)
AU (2) AU2014233363B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023753A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903871A1 (cg-RX-API-DMAC7.html)
ES (2) ES2766326T3 (cg-RX-API-DMAC7.html)
GB (3) GB2540638B (cg-RX-API-DMAC7.html)
HK (2) HK1219836A1 (cg-RX-API-DMAC7.html)
IL (2) IL240786B (cg-RX-API-DMAC7.html)
MX (1) MX371382B (cg-RX-API-DMAC7.html)
MY (1) MY171945A (cg-RX-API-DMAC7.html)
PH (2) PH12015502153B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507131WA (cg-RX-API-DMAC7.html)
WO (1) WO2014145068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
AU2010313785C1 (en) 2009-10-30 2019-04-11 Ix Biopharma Ltd Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
PL2496236T4 (pl) 2009-11-06 2015-11-30 Aerpio Therapeutics Inc Inhibitory hydroksylazy prolilowej
US20180092883A1 (en) * 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CN103347561B (zh) 2010-12-08 2016-09-07 康沃特克科技公司 用于评估伤口分泌液的集成系统
CN103347562B (zh) 2010-12-08 2016-08-10 康沃特克科技公司 伤口分泌液系统附件
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
HK1201438A1 (en) 2011-10-13 2015-09-04 Aerpio Therapeutics, Inc. Treatment of ocular disease
CN104812378B (zh) * 2012-10-11 2017-12-01 Ix生物制药有限公司 固体剂型
US9440963B2 (en) * 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106232120B (zh) 2014-02-19 2021-01-08 爱尔皮奥治疗有限公司 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
EP4414032A3 (en) 2015-09-23 2024-11-06 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of tie-2
EP3364674B1 (en) * 2015-11-06 2019-10-09 Huawei Technologies Co., Ltd. Voice roaming method, mobility management network element, and access network element
CN109715189B (zh) 2016-07-20 2025-01-03 视点制药公司 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
AU2020259450A1 (en) * 2019-04-18 2021-11-18 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of Tie-2
AU2020264969B2 (en) * 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
GB2589400A (en) * 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof
CA3156225A1 (en) 2019-10-29 2021-05-06 EyePoint Pharmaceuticals, Inc. Small molecule activators of tie-2
CN117460743A (zh) * 2020-06-16 2024-01-26 曼宁研究公司 小分子ve-ptp抑制剂
WO2022133232A1 (en) * 2020-12-18 2022-06-23 EyePoint Pharmaceuticals, Inc. Methods for manufacture of small molecule activators of tie-2
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081172A1 (en) * 2009-01-12 2010-07-15 Akebia Therapeutics Inc. Methods for treating vascular leak syndrome
EP2269621A1 (en) * 2008-03-31 2011-01-05 Shiseido Company, Ltd. Agents for maturing, normalizing or stabilizing blood vessels and wrinkle-preventing and improving agents
EP2319537A1 (en) * 2008-06-18 2011-05-11 Shiseido Company, Ltd. Stabilizer for lymph vessel
JP2011201811A (ja) * 2010-03-25 2011-10-13 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
EP2857032A2 (en) * 2010-12-02 2015-04-08 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6455031B1 (en) * 1997-06-18 2002-09-24 David G Davies Methods and compositions for controlling biofilm development
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
DE60003011T2 (de) 1999-03-26 2004-04-08 Regeneron Pharmaceuticals, Inc. Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
HUP0302779A3 (en) 2000-06-23 2005-12-28 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
KR20040025880A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 수용해성이 개선된 의약 조성물
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
US7166435B2 (en) * 2001-08-06 2007-01-23 The Quigley Corporation Compositions and methods for reducing the transmissivity of illnesses
US20030158199A1 (en) * 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤
JP4881725B2 (ja) * 2003-04-09 2012-02-22 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
RS20160203A1 (sr) * 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
WO2005118639A1 (en) * 2004-06-02 2005-12-15 Valtion Teknillinen Tutkimuskeskus Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
SI1968594T1 (sl) 2005-11-29 2011-01-31 Glaxosmithkline Llc Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema
AU2006324477A1 (en) 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
WO2007091622A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) * 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008027013A2 (en) * 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
WO2008049227A1 (en) * 2006-10-27 2008-05-02 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
DK1932558T3 (da) 2006-12-13 2011-09-05 Shl Group Ab Autoinjektor
CN101678170B (zh) 2007-03-23 2012-05-30 Shl集团有限责任公司 自动注射器
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009007229A1 (en) 2007-07-06 2009-01-15 Shl Medical Ab One shot injector with dual springs
US8038649B2 (en) 2007-09-18 2011-10-18 Shl Group Ab Automatic injection device with needle insertion
AU2009249848B2 (en) 2008-05-20 2012-03-29 Shl Group Ab Device for a medicament delivery device
CN102112165B (zh) 2008-06-11 2013-05-29 Shl集团有限责任公司 药物输送设备
JP4751482B2 (ja) * 2008-07-22 2011-08-17 株式会社メニコン コンタクトレンズ用液剤
EP2378609A1 (en) 2008-12-22 2011-10-19 Fujikura, Ltd. Film antenna and method for manufacturing the same
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX2011007420A (es) 2009-07-06 2011-12-14 Akebia Therapeutics Inc Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
PL2496236T4 (pl) 2009-11-06 2015-11-30 Aerpio Therapeutics Inc Inhibitory hydroksylazy prolilowej
US20110319455A1 (en) 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
CA2797247C (en) * 2010-04-28 2019-10-22 Sunnybrook Health Sciences Centre Methods and uses of tie2 binding and/or activating agents
BR112013008452A2 (pt) 2010-10-07 2016-06-28 Aerpio Therapeutics Inc composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
JP2014508749A (ja) 2011-02-11 2014-04-10 サイヴィーダ ユーエス，インコーポレイテッド 抗浮腫治療薬を使用する黄斑浮腫の治療方法
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
HK1201438A1 (en) 2011-10-13 2015-09-04 Aerpio Therapeutics, Inc. Treatment of ocular disease
US20150050277A1 (en) * 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9440963B2 (en) 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
CN106232120B (zh) 2014-02-19 2021-01-08 爱尔皮奥治疗有限公司 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269621A1 (en) * 2008-03-31 2011-01-05 Shiseido Company, Ltd. Agents for maturing, normalizing or stabilizing blood vessels and wrinkle-preventing and improving agents
EP2319537A1 (en) * 2008-06-18 2011-05-11 Shiseido Company, Ltd. Stabilizer for lymph vessel
WO2010081172A1 (en) * 2009-01-12 2010-07-15 Akebia Therapeutics Inc. Methods for treating vascular leak syndrome
JP2011201811A (ja) * 2010-03-25 2011-10-13 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
EP2857032A2 (en) * 2010-12-02 2015-04-08 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition

Also Published As

Publication number Publication date
AU2014233363A1 (en) 2015-10-22
CN105307498A (zh) 2016-02-03
PH12019502018A1 (en) 2020-07-06
AU2014233363B2 (en) 2017-06-29
MY171945A (en) 2019-11-08
GB2540638A8 (en) 2017-03-15
US20180237430A1 (en) 2018-08-23
JP6572201B2 (ja) 2019-09-04
GB201520656D0 (en) 2016-01-06
BR112015023753A2 (pt) 2017-07-18
GB2516561A (en) 2015-01-28
US20180237429A1 (en) 2018-08-23
MX2015011131A (es) 2016-03-04
IL240786B (en) 2019-07-31
AU2017235953A1 (en) 2017-10-19
MX371382B (es) 2020-01-28
GB2540638A (en) 2017-01-25
US20200361926A1 (en) 2020-11-19
EP2967066A1 (en) 2016-01-20
EP3607821A1 (en) 2020-02-12
CN109925312A (zh) 2019-06-25
WO2014145068A1 (en) 2014-09-18
EP4101297A1 (en) 2022-12-14
JP2019218370A (ja) 2019-12-26
US9440963B2 (en) 2016-09-13
CA2903871A1 (en) 2014-09-18
AU2017235953B2 (en) 2019-12-05
US20140275103A1 (en) 2014-09-18
EP2967066A4 (en) 2016-11-02
SG11201507131WA (en) 2015-10-29
US20160220541A1 (en) 2016-08-04
US20160220540A1 (en) 2016-08-04
US20180251457A1 (en) 2018-09-06
GB2549865A (en) 2017-11-01
CN105307498B (zh) 2019-04-16
HK1206558A1 (en) 2016-01-15
US20180237431A1 (en) 2018-08-23
GB201411935D0 (en) 2014-08-20
EP3607821B1 (en) 2022-08-03
JP6865254B2 (ja) 2021-04-28
PH12015502153A1 (en) 2016-01-25
JP7249374B2 (ja) 2023-03-30
US12152023B2 (en) 2024-11-26
GB201709419D0 (en) 2017-07-26
JP2021100979A (ja) 2021-07-08
KR20150129019A (ko) 2015-11-18
US20180022741A1 (en) 2018-01-25
US20220274976A1 (en) 2022-09-01
PH12015502153B1 (en) 2019-11-29
IL240786A0 (en) 2015-10-29
EP2967066B1 (en) 2019-10-23
GB2549865B (en) 2018-01-17
GB2516561B (en) 2016-03-09
JP2016516068A (ja) 2016-06-02
ES2766326T3 (es) 2020-06-12
HK1219836A1 (zh) 2017-04-21
IL267997A (en) 2019-09-26
ES2928162T3 (es) 2022-11-15

Similar Documents

Publication Publication Date Title
GB2549865B (en) Formulations comprising a compound that activates Tie-2 and their use in treating ocular diseases
IL304851A (en) Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
IL260511B (en) Prodrugs of fumarates and their use in the treatment of various diseases
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
GB201319621D0 (en) Antimicrobial agents and their use in therapy
IL239735A0 (en) Treatment and diseases associated with toxic aldehyde
PL3010506T3 (pl) Pridopidyna w leczeniu choroby huntingtona
SG11201509259RA (en) Bispecific constructs and their use in the treatment of various diseases
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
SI2945642T1 (sl) Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
GB201311361D0 (en) Compounds and their therapeutic use
GB201308736D0 (en) Compounds and their therapeutic use
GB201308753D0 (en) Compounds and their use in therapy
GB201308217D0 (en) Compounds and their use in therapy
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
IL243094A0 (en) History of hyperforin and its use in Alzheimer's disease
GB201312128D0 (en) Drug combination and its use in therapy
GB201312131D0 (en) Drug combination and its use in therapy
GB201312129D0 (en) Drug combination and its use in therapy
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use